Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Tony S MokYing ChengXiangdong ZhouKi Hyeong LeeKazuhiko NakagawaSeiji NihoAlka ChawlaRafael RosellJesus CorralMaria Rita MigliorinoAdam PluzanskiKay NoonanYiyun TangMalaika PastelKeith D WilnerYi-Long WuPublished in: Drugs (2021)
The OS benefit from first-line treatment with dacomitinib versus gefitinib was maintained after extended follow-up in patients with advanced NSCLC with EGFR-activating mutations. CLINICALTRIALS.GOV: NCT01774721 (registered 24 January 2013).